Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARI-HER2
- Development stage
- Unknown
- Lead developer
- IDIBAPS – the Hospital Clinic of the University of Barcelona
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ARI-HER2 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the Human Epidermal Growth Factor Receptor 2 (HER2). Developed by the Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) in collaboration with Hospital Clínic de Barcelona, it is designed to treat advanced HER2-positive solid tumors, specifically breast cancer. The therapy involves genetically modifying a patient's own T cells to express a CAR that recognizes and binds to HER2-expressing cancer cells, leading to T-cell activation and tumor cell lysis. It is currently being evaluated in Phase 1 clinical trials for patients with advanced HER2-positive breast cancer who have exhausted standard treatment options.
- Other names
- HER2-CAR-THER-2-CAR-THER 2-CAR-TARI-HER2 CAR-TARI-HER-2 CAR-TARI-HER 2 CAR-T
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ARI-HER2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARI-HER2.